Cargando…
Androgen therapy and atherosclerotic cardiovascular disease
Cardiovascular disease (CVD) remains the leading cause of death in Western society today. There is a striking gender difference in CVD with men predisposed to earlier onset and more severe disease. Following the recent reevaluation and ongoing debate regarding the estrogen protection hypothesis, and...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2464747/ https://www.ncbi.nlm.nih.gov/pubmed/18629352 |
_version_ | 1782157437549150208 |
---|---|
author | McGrath, K-CY McRobb, LS Heather, AK |
author_facet | McGrath, K-CY McRobb, LS Heather, AK |
author_sort | McGrath, K-CY |
collection | PubMed |
description | Cardiovascular disease (CVD) remains the leading cause of death in Western society today. There is a striking gender difference in CVD with men predisposed to earlier onset and more severe disease. Following the recent reevaluation and ongoing debate regarding the estrogen protection hypothesis, and given that androgen use and abuse is increasing in our society, the alternate view that androgens may promote CVD in men is assuming increasing importance. Whether androgens adversely affect CVD in either men or women remains a contentious issue within both the cardiovascular and endocrinological fraternities. This review draws from basic science, animal and clinical studies to outline our current understanding regarding androgen effects on atherosclerosis, the major CVD, and asks where future directions of atherosclerosis-related androgen research may lie. |
format | Text |
id | pubmed-2464747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-24647472008-07-15 Androgen therapy and atherosclerotic cardiovascular disease McGrath, K-CY McRobb, LS Heather, AK Vasc Health Risk Manag Review Cardiovascular disease (CVD) remains the leading cause of death in Western society today. There is a striking gender difference in CVD with men predisposed to earlier onset and more severe disease. Following the recent reevaluation and ongoing debate regarding the estrogen protection hypothesis, and given that androgen use and abuse is increasing in our society, the alternate view that androgens may promote CVD in men is assuming increasing importance. Whether androgens adversely affect CVD in either men or women remains a contentious issue within both the cardiovascular and endocrinological fraternities. This review draws from basic science, animal and clinical studies to outline our current understanding regarding androgen effects on atherosclerosis, the major CVD, and asks where future directions of atherosclerosis-related androgen research may lie. Dove Medical Press 2008-02 /pmc/articles/PMC2464747/ /pubmed/18629352 Text en © 2008 Dove Medical Press Limited. All rights reserved |
spellingShingle | Review McGrath, K-CY McRobb, LS Heather, AK Androgen therapy and atherosclerotic cardiovascular disease |
title | Androgen therapy and atherosclerotic cardiovascular disease |
title_full | Androgen therapy and atherosclerotic cardiovascular disease |
title_fullStr | Androgen therapy and atherosclerotic cardiovascular disease |
title_full_unstemmed | Androgen therapy and atherosclerotic cardiovascular disease |
title_short | Androgen therapy and atherosclerotic cardiovascular disease |
title_sort | androgen therapy and atherosclerotic cardiovascular disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2464747/ https://www.ncbi.nlm.nih.gov/pubmed/18629352 |
work_keys_str_mv | AT mcgrathkcy androgentherapyandatheroscleroticcardiovasculardisease AT mcrobbls androgentherapyandatheroscleroticcardiovasculardisease AT heatherak androgentherapyandatheroscleroticcardiovasculardisease |